This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01137682
First received: May 27, 2010
Last updated: April 28, 2017
Last verified: April 2017
Results First Received: January 13, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230)
Drug: octreotide LAR 30mg
Drug: lanreotide ATG 120mg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
6 Patients were not treated. 2 patients did not receive any study medication but had incorrect data entered in dosing CRF and therefore listed as treated below.

Reporting Groups
  Description
Pasireotide LAR 40 mg Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
Pasireotide LAR 60 mg Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
Control Arm (Octreotide or Lanreotide) If a patient is randomized to the open label arm the investigator will either: • be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or • continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations.

Participant Flow:   Overall Study
    Pasireotide LAR 40 mg   Pasireotide LAR 60 mg   Control Arm (Octreotide or Lanreotide)
STARTED   65   65   68 
Not Treated   2   1   1 
Treated   63   64   67 
Completed 24-Week Core Phase   59   57   65 
Not Continuing Into Extension   3   4   3 
Continuing Into Extension   56   53   62 
Safety Set   63 [1]   62 [2]   66 [1] 
COMPLETED   59   57   65 
NOT COMPLETED   6   8   3 
Adverse Event                2                4                0 
Withdrawal by Subject                2                2                2 
Administrative Problems                2                1                0 
Protocol Violation                0                1                1 
[1] 2 patients never received drug.
[2] 2 patients never received drug. 1 patient had no post baseline safety assement.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pasireotide LAR 40 mg Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
Pasireotide LAR 60 mg Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
Control Arm (Octreotide or Lanreotide) If a patient is randomized to the open label arm the investigator will either: • be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or • continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations.
Total Total of all reporting groups

Baseline Measures
   Pasireotide LAR 40 mg   Pasireotide LAR 60 mg   Control Arm (Octreotide or Lanreotide)   Total 
Overall Participants Analyzed 
[Units: Participants]
 65   65   68   198 
Age, Customized 
[Units: Participants]
       
<65 Years   62   57   63   182 
≥ 65 Years   3   8   5   16 
Sex: Female, Male 
[Units: Participants]
Count of Participants
       
Female      38  58.5%      35  53.8%      38  55.9%      111  56.1% 
Male      27  41.5%      30  46.2%      30  44.1%      87  43.9% 
Race/Ethnicity, Customized 
[Units: Participants]
       
Caucasian   53   52   56   161 
Black   3   8   4   15 
Other   4   3   7   14 
Native American   2   1   1   4 
Asian   3   1   0   4 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.   [ Time Frame: 24 weeks ]

2.  Secondary:   Perecentage of Participants Achieving Normalization of Sex- and Age-adjusted IGF-1   [ Time Frame: 24 weeks ]

3.  Secondary:   Percentage of Participants Achieving Biochemical Control Defined as Mean GH Levels < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.   [ Time Frame: 12 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

4.  Secondary:   Percentage of Participants Achieving GH Levels < 2.5 µg/L.   [ Time Frame: Weeks 12 and 24 ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

5.  Secondary:   Percentage of of Participants Achieving GH Levels < 1 µg/L and Normal, Sex- and Age-adjusted IGF-1.   [ Time Frame: Weeks 12 and 24 ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

6.  Secondary:   Percentage of Participants Achieving GH Levels < 1 µg/L.   [ Time Frame: Weeks 12 and 24 ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

7.  Secondary:   Percentage of Participants Achieving a Tumor Volume Reduction > 25% Assessed by Pituitary MRI.   [ Time Frame: 24 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

8.  Secondary:   Percent Change in Tumor Volume Assessed by Pituitary MRI.   [ Time Frame: Baseline, 24 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

9.  Secondary:   Change From Baseline in Clinical Signs/Symptoms of Acromegaly (Ring Size; Headache, Fatigue, Perspiration, Paresthesias and Osteoarthralgia According to a Five-point Score Scale)   [ Time Frame: Baseline, 24 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

10.  Secondary:   Change From Baseline in Health Related QoL as Measured by the AcroQoL (Acromegaly Health Related QoL)   [ Time Frame: Baseline, 24 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  

11.  Secondary:   PK Levels of Pasireotide LAR 40 mg and Pasireotide LAR 60 mg   [ Time Frame: 24 Weeks ]
Results not yet reported.   Anticipated Reporting Date:   02/2018  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862-778-8300
e-mail: trialandresults.registries@novartis.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01137682     History of Changes
Other Study ID Numbers: CSOM230C2402
EUDRACT 2009-016722-13 ( Registry Identifier: EUDRACT )
Study First Received: May 27, 2010
Results First Received: January 13, 2015
Last Updated: April 28, 2017